Innate Pharma Files 6-K Report
Ticker: IPHA · Form: 6-K · Filed: Apr 13, 2026
Sentiment: neutral
Topics: foreign-issuer, sec-filing, regulatory-update
TL;DR
Innate Pharma filed a 6-K on 4/13/26, check EX-99.1 for details.
AI Summary
Innate Pharma SA filed a 6-K report on April 13, 2026. The filing includes a document labeled EX-99.1, which is an exhibit to the report. The company is based in Marseille, France, and operates in the Biological Products sector.
Why It Matters
This filing provides an update from Innate Pharma SA, a foreign issuer, to the SEC, potentially containing important operational or financial information for investors.
Risk Assessment
Risk Level: low — A 6-K filing is a routine report for foreign issuers and typically does not contain significant new material information that would immediately impact risk.
Key Players & Entities
- Innate Pharma SA (company) — Filer of the 6-K report
- 0001598599 (company) — CIK number for Innate Pharma SA
- 2026-04-13 (date) — Filing date and period of report
- EX-99.1 (document) — Exhibit filed with the 6-K
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign issuer required by SEC rules 13a-16 and 15d-16, used to provide information that the issuer makes public in its home country or distributes to its security holders.
When was this specific 6-K filing accepted by the SEC?
This 6-K filing was accepted by the SEC on April 13, 2026.
What is the CIK number for Innate Pharma SA?
The CIK number for Innate Pharma SA is 0001598599.
What is the SIC code listed for Innate Pharma SA?
The SIC code listed for Innate Pharma SA is 2836, which corresponds to Biological Products, (No Diagnostic Substances).
Where is Innate Pharma SA located?
Innate Pharma SA is located in Marseille, France, with both its mailing and business addresses at 117 Avenue de Luminy BP 30191.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 13, 2026 regarding Innate Pharma SA (IPHA).